Get the Stockscreener App
19.19
2.68%
0.50
After Hours:
19.05
-0.14
-0.73%
Moonlake Immunotherapeutics stock is traded at $19.19, with a volume of 575.71K.
It is up +2.68% in the last 24 hours and up +9.34% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$18.69
Open:
$19
24h Volume:
575.71K
Relative Volume:
0.59
Market Cap:
$1.41B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-5.4426
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
+6.61%
1M Performance:
+9.34%
6M Performance:
+34.01%
1Y Performance:
-56.59%
1-Day Range:
$18.65
$19.21
1-Week Range:
$17.00
$19.21
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
19.19 | 1.38B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
[144] MoonLake Immunotherapeutics SEC Filing - Stock Titan
Why did MLTX stock rise after-hours today? - MSN
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
How Sonelokimab’s FDA Pre-BLA Milestone And EULAR Data At MoonLake Immunotherapeutics (MLTX) Has Changed Its Investment Story - simplywall.st
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Slides 1.7% as Biotech Sector Pressure Weighs, Support at $16.62 in FocusCommon Gap - newsline.com
InvestingPro Fair Value catches MoonLake before 63% biotech surge By Investing.com - Investing.com India
MoonLake (NASDAQ: MLTX) shareholders approve equity plan expansion and re-elect director - Stock Titan
MLTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
Why Did MLTX Stock Rise After-Hours Today? - Stocktwits
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on axSpA data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Moonlake stock rating on axSpA data - Investing.com
MLTX Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates, Stock DeclinesLong-Term Guidance - newsline.com
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention - simplywall.st
Trading Systems Reacting to (MLTX) Volatility - Stock Traders Daily
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? - AOL.com
MoonLake earnings in focus: BLA path for sonelokimab takes center stage - Investing.com
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress - Insider Monkey
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma - The Globe and Mail
MoonLake Immunotherapeutics Signs Manufacturing Agreement with Vetter Pharma – SEC 8-K Filing Details 8 - Minichart
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter - Investing.com UK
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter By Investing.com - Investing.com South Africa
MoonLake (NASDAQ: MLTX) secures Vetter supply and capacity agreements - Stock Titan
MoonLake Immunotherapeutics | 8-K: Current report - Moomoo
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):